Novo Nordisk’s Ozempic and Wegovy, long in shortage, are now listed as available by FDA
Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage list for over two years, with different doses being listed in shortage at various times.
As if there weren't enough reasons to buy shares of the cardiometabolic drug juggernauts Eli Lilly (LLY 0.74%) and Novo Nordisk (NVO -0.28%), there's now one more big reason to ex ...
Novo Nordisk (NVO) has released an update. Novo Nordisk has been actively engaged in a share repurchase program, aiming to buy back B shares ...
A former regional account manager working for Novo Nordisk Inc. is suing the healthcare company, alleging it failed to ...
The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...
Hims & Hers (HIMS) stock fell 14% following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer ...
The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of ...
Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback